A novel therapeutic giving cancer patients new hope.
We are focused on rapidly advancing our lead therapeutic candidate, misetionamide (GP-2250), for the treatment of multiple cancer types including ovarian and pancreatic cancers.
Our Science
Disrupting cancer cell metabolism.
Our unique and novel mechanism of action selectively disrupts the energy metabolism of cancer cells leading to cancer cell death as well as impacting nuclear factor-κB (“NFκB”) which effects cancer cells’ ability for protein synthesis and DNA transcription thereby restricting cancer cell growth and proliferation.
Our PIPELINE
Focused on Addressing Unmet Needs for Patients with Cancer.
Pancreatic
Cancer
Ovarian
Cancer
Additional
Targets
Melanoma, Squamous Cell, Breast, Colorectal
Truly novel.
Truly important.
We are on a mission to improve therapeutic outcomes for cancer patients with GP-2250, a tumor-cell selective agent with a truly novel mechanism of action.
Focused on what matters most.
While GP-2250 has demonstrated broad utility across a number of indications and therapeutic uses in preclinical and Phase 1 clinical studies, including where inflammatory cytokine suppression could be of therapeutic value, we have chosen to focus on the treatment of pancreatic and ovarian cancers as our initial targets, two conditions with a clear unmet need. Early clinical experience is promising.
